CancerLinQ LLC, a wholly owned nonprofit of ASCO, announced today that more than 1 million patient records are now in the CancerLinQ™ platform. In addition, 70 practices have signed agreements to participate in CancerLinQ, representing more than 1,500 oncologists.

"We are excited to reach this milestone and continue to be awed and inspired by the engagement and support from the oncology community," said CancerLinQ LLC CEO Kevin Fitzpatrick. "As more records enter the CancerLinQ platform, it will enhance participating oncologists' ability to improve the quality of care that they provide." 

CancerLinQ is a powerful platform containing growing amounts of real-world cancer information. This national initiative will allow cancer providers to improve the quality and value of care by analyzing the medical records of millions of patients with cancer, uncovering patterns and trends, and measuring their care against that of their peers and recommended guidelines. CancerLinQ was co-developed with SAP, utilizing the SAP Connected Health platform that runs on SAP HANA, a flexible, in-memory data management and application platform.

CancerLinQ LLC has completed agreements with 70 oncology practices in 39 states and the District of Columbia, and is potentially available to any practice nationwide. Participants range from small private practices to some of the nation's leading cancer centers. CancerLinQ has also successfully connected with most major electronic health record systems, including both enterprise and oncology-specific systems, showing data can be shared seamlessly and securely across technical platforms. View the list of practices participating in CancerLinQ.

CancerLinQ is supported in part through the Conquer Cancer Foundation, whose generous donors have helped make the system possible. Major supporters include Amgen; Astellas; AstraZeneca; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cancer Treatment Centers of America^®; Chan Soon-Shiong Family Foundation; Genentech BioOncology™; HELSINN; Janssen Oncology; Lilly; Novartis Oncology; Pfizer Oncology; Raj Mantena, RPh; Susan G. Komen^®; and Thomas G. Roberts, Jr., MD, and Susan M. DaSilva.